BioCentury | Oct 17, 2020
Finance

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos and Tarsus...
BioCentury | Oct 1, 2020
Distillery Therapeutics

Calcium channel-targeting peptide to prevent hypertrophic cardiomyopathy

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy A peptide targeting the cardiac calcium channel L-type α-interaction domain, a cytoplasmic portion the channel’s α1C subunit, could prevent hypertrophic cardiomyopathy. In a mouse model of the disease caused by a...
BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

Jazz gains essential tremor asset via Cavion takeout Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory and sales milestones in a deal that...
BioCentury | Dec 12, 2018
Distillery Therapeutics

Cardiovascular

...antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that the generic calcium channel N-type...
BioCentury | Oct 11, 2018
Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
BioCentury | Oct 8, 2018
Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
BioCentury | Feb 14, 2018
Preclinical News

Three targets in the same brain region could alleviate depression

A Zhejiang University team published a pair of papers in Nature suggesting ketamine works by modulating the firing of neurons in the lateral habenula, a brain region that controls reward signaling. The studies point to...
BioCentury | May 8, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting the calcium channel L-type could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a calcium channel L-type inhibitor decreased MS symptom scores,...
BioCentury | Mar 30, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified calcium channel T-type and potassium channel inhibitors that could help treat glioblastoma. Screening of a library of ion channel blockers against primary human glioblastoma cell lines...
BioCentury | Jul 20, 2015
Clinical News

Horizant gabapentin enacarbil: Phase II started

...Horizant gabapentin enacarbil ( Regnite ) ( GSK1838262 , XP13512 ) Business: Neurology Molecular target: Calcium channel N-type...
Items per page:
1 - 10 of 37